Effects of specific immunotherapy on the development of new sensitisations in monosensitised XXXX .

@entity6542 @entity1 @entity2023 @entity235 @entity565 @entity2490 @entity402 @entity56 @entity1576
BACKGROUND: @entity6542 ( @entity6542 ) is the only treatment that interferes with the basic pathophysiological mechanisms of @entity56 and is widely used in the management of clinically significant respiratory IgE-mediated diseases. Nevertheless, until recently, information on the influence of @entity6542 on the development of @entity56 has been scant. METHODS: One hundred consecutive @entity1 (45 males and 55 females, aged 6 to 69 years) with @entity1576 and attending the allergy unit of a general hospital were selected. All had been diagnosed by clinical history and skin prick tests of @entity2023 and/or @entity565 , were monosensitised (71 to Dermatophagoides spp, 22 to Parietaria judaica pollen and 7 to grass pollen) and had been followed up as outpatients between 1990-98. Sixty-six @entity1 had been treated with conventional @entity6542 for at least 3 years, while thirty-four followed only environmental measures and drug treatment. @entity402 status (first-degree relatives), smoking, family pets (cat and/or @entity235 ), @entity2490 and/or @entity565 symptom score and inhalant skin prick tests to the same aeroallergens were compared between baseline and after 3 to 5 years of treatment. RESULTS: No statistically-significant differences in the development of new sensitisations were observed between the two groups (36.4 % of @entity6542 -treated @entity1 versus 38.2 % in control group, RR = 0.97, CI 95 %: 0.72-1.3). Smoking, family atopy history and pets did not appear to be risk factors for the development of neosensitisations (p < 0.05). Nevertheless, @entity6542 -treated @entity1 presented a better clinical score than the control group, with improvements of 89.4 % and 61.8 %, respectively (p = 0.007). CONCLUSIONS: Three-year @entity6542 did not protect against development of new sensitisations in monosensitised @entity2023 or @entity565 . Smoking, family atopy history and pets were not associated with development of new sensitisations. Clinical score improved significantly in the @entity6542 -treated group compared with drug-treated @entity1 .
